Episode 2: Corporate reputation in the age of GLP-1
Update: 2025-06-05
Description
Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting investor confidence, discover how these drugs are rewriting the rules for pharma brands.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
